Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-JNJ26489112 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 14C-JNJ26489112 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 14C-JNJ26489112 | DRUG | Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1. |
Inclusion Criteria: * Signed an informed consent document indicating they understand the purpose of and procedures required for the study, are willing to participate in the study, and are willing to adhere to the prohibitions and restrictions specified in the protocol * Had consistent bowel movemen...
14C-JNJ26489112 is an investigational small molecule developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy male participants. The compound is radiolabeled with carbon-14, a labeling approach used in early research to trace how a drug is absorbed, metabolized, and excreted by the body.
14C-JNJ26489112 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound. No partner or collaborator is identified for this asset.
14C-JNJ26489112 is in Phase 1 clinical development. Its single recorded trial, NCT01949610, has been completed. The study was an open-label, uncontrolled Phase 1 trial, so it was not randomized and not double blinded. The compound is investigational and has not been approved by the FDA.
14C-JNJ26489112 has been evaluated in one clinical trial, NCT01949610, titled A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants. The Phase 1 study enrolled 10 healthy male volunteers aged 18 years and older in Belgium and is now completed.
The Phase 1 trial NCT01949610 was designed to evaluate the absorption, metabolism, and excretion of 14C-JNJ26489112 in healthy male participants. It enrolled 10 volunteers in Belgium. The carbon-14 label allows researchers to track where the compound and its breakdown products go in the body after dosing.